Zyprexa Articles
Significant Increases For US Drug Firms In 1996
3 February 1997
Record Number Of New Chemical Entities In 1996
20 January 1997
Continued Approval Of Blockbuster Products In '97?
23 December 1996
Product News In 1996 Dominated By CNS
23 December 1996
EU CPMP October Meeting
28 October 1996
Lilly Launches Zyprexa In Its First Markets
21 October 1996
NEW YORK STOCK COMMENT
7 October 1996
Zyprexa Gains 1st Approvals In USA/EU For Schizophrenia
7 October 1996
New York Stock Comment
9 September 1996
New US Drug Approvals Announced
9 September 1996
Zeneca Files First European Seroquel Dossier
19 August 1996
New York Stock Comment
5 August 1996
US Drug Majors See 2nd-Half Double-Digit Growth
29 July 1996
Lilly Cuts Costs As It Launches New Products
15 July 1996
First Appro Of Sertindole In UK; Launch Imminent
1 July 1996
New York Stock Comment
10 June 1996
New York Stock Comment
29 April 1996
Atypical Antipsychotic Cuts Schizophrenia Costs
8 April 1996
Abbott's Sertindole At ACP Meeting
22 January 1996
Phase III Data With Lilly's Olanzapine
8 January 1996
Zeneca Reveals Typically Strong Pipeline
18 December 1995
New York Stock Comment
4 December 1995
NEW YORK STOCK COMMENT
2 October 1995
Lilly Submits Olanzapine For Approval Worldwide
2 October 1995
European Markets For Neuroleptic drugs
7 August 1995
Eli Lilly Set For Overseas Expansion
10 July 1995
The ABPI's A-Z Of British Medicines Research
29 May 1995
Phase II Results With Lilly's Olanzapine
18 July 1994
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- New study shows UCB's Neupro reduces NSBP in RLS patient
